HOLLISTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Micro Cap Virtual Conference taking place on May 10th, 2023.
Mr. Green will present on Wednesday, May 10th at 11:30 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard Bioscience website for a limited period of time.
Harvard Bioscience will also host virtual one-on-one meetings with investors on Wednesday, May 10th, 2023
To register for the presentation or to schedule a one-on-one meeting, please visit www.sidoti.com/events.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com.
Investor Contact:
Harvard Bioscience, Inc.
Investor Relations
(508) 893-3120
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.38 |
Daily Change: | -0.02 -5.07 |
Daily Volume: | 325,254 |
Market Cap: | US$16.580M |
February 24, 2025 November 07, 2024 October 03, 2024 September 18, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load